{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below by stage for Phase I patients.","groups":[{"description":"Patients receive MV-NIS IV over 1 hour on day 1. (Closed to accrual on 12/17/2009 and reopened 10/13/2011)","id":"OG000","title":"Phase I: Stage 1 (MV-NIS Alone)"},{"description":"Patients receive 10 mg/kg cyclophosphamide IV over 30 minutes and then MV-NIS IV over 1 hour 2 days later. (Temporarily closed to accrual on 10/13/11)","id":"OG001","title":"Phase I: Stage 2 (MV-NIS and Cyclophosphamide)"}],"paramType":"NUMBER","populationDescription":"Per protocol, Phase I specified secondary endpoint is evaluated for each STAGE independently; thus, the stage 1 dose level groups were combined and the stage 2 dose level groups were combined for this analysis PER PROTOCOL.","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Overall Toxicity Rate, Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0) (Phase I)","type":"SECONDARY","unitOfMeasure":"percentage of patients"}